Niche CRO Focus Biotranex operates as a science-driven CRO specializing in ADMET, pharmacokinetic services, and regulatory filings support, signaling opportunities to upsell advanced in vitro/in vivo testing, metabolite profiling, and DMPK consultations to small biotech and early-stage pharma clients seeking IND/NDA assistance.

High Potential Clients With 2-10 employees and <$1M revenue, Biotranex likely serves startups and emerging biotech firms; sales opportunities include helping scale their ADMET capabilities, offering modular CRO services, and establishing long-term retainer arrangements as clients grow.

Regulatory Readiness The team’s extensive experience with IND and NDA filings positions Biotranex as a partner for clients aiming to accelerate regulatory milestones; potential upsells include regulatory strategy alignment, data package preparation, and nonclinical-to-clinical transition support.

Comprehensive ADMET Suite Biotranex offers a broad range of ADMET and PK services (CYP/UGT phenotyping, transporter studies, biotransformation, metabolite biosynthesis, etc.), presenting cross-sell opportunities to labs or CROs seeking to augment existing pathways or fill gaps in endothelial/biopharma development programs.

Tech Modernization Needs Current technology stack includes Joomla and older web technologies, suggesting a potential services angle around IT/biotech data management, secure lab information management system (LIMS) integration, or interface modernization projects that could be bundled with scientific services for clients prioritizing digital workflows.